Timothy F Burns

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 15

Top Topics

Advanced Non Small Cell Lung Cancer

Dna Methylation

Epidermal Growth Factor Receptor

Top Venues

Cancer research communications

Cancer research

NPJ precision oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Edward B Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A Trikalinos, Arash Rezazadeh Kalebasty, Mamta Parikh, Scott A Boerner, Celene Balido, Gregor Krings, Timothy F Burns, Emily K Bergsland, Pamela N Munster, Alan Ashworth, Patricia M LoRusso, Rahul R Aggarwal
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer research communications 4 (7) (2024)
Vinod Kumar, Zachary A Yochum, Princey Devadassan, Eric H-B Huang, Ethan Miller, Roja Baruwal, Purva H Rumde, Autumn L GaitherDavis, Laura P Stabile, Timothy F Burns
TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer. Oncogene (2024)
Vinod Kumar, Zachary A Yochum, Princey Devadassan, Eric H-B Huang, Ethan Miller, Roja Baruwal, Purva H Rumde, Autumn L GaitherDavis, Laura P Stabile, Timothy F Burns
TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer. Oncogene 43 (19) (2024)
Edward B Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A Trikalinos, Arash Rezazadeh Kalebasty, Mamta Parikh, Scott A Boerner, Celene Balido, Gregor Krings, Timothy F Burns, Emily K Bergsland, Pamela N Munster, Alan Ashworth, Patricia M LoRusso, Rahul R Aggarwal
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer research communications 4 (7) (2024)
Edward B Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A Trikalinos, Arash Rezazadeh Kalebasty, Mamta Parikh, Scott A Boerner, Celene Balido, Gregor Krings, Timothy F Burns, Emily K Bergsland, Pamela N Munster, Alan Ashworth, Patricia M LoRusso, Rahul R Aggarwal
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer research communications 4 (7) (2024)
Purva H Rumde, Timothy F Burns
A Path to Persistence after EGFR Inhibition. Cancer research 84 (8) (2024)
Edward B Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A Trikalinos, Arash Rezazadeh Kalebasty, Mamta Parikh, Scott A Boerner, Celene Balido, Gregor Krings, Timothy F Burns, Emily K Bergsland, Pamela N Munster, Alan Ashworth, Patricia M LoRusso, Rahul R Aggarwal
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer research communications (2024)
Vinod Kumar, Zachary A Yochum, Princey Devadassan, Eric H-B Huang, Ethan Miller, Roja Baruwal, Purva H Rumde, Autumn L GaitherDavis, Laura P Stabile, Timothy F Burns
TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer. Oncogene 43 (19) (2024)
Purva H Rumde, Timothy F Burns
A Path to Persistence after EGFR Inhibition. Cancer research 84 (8) (2024)
Vinod Kumar, Zachary A Yochum, Princey Devadassan, Eric H-B Huang, Ethan Miller, Roja Baruwal, Purva H Rumde, Autumn L GaitherDavis, Laura P Stabile, Timothy F Burns
TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer. Oncogene (2024)
Vinod Kumar, Zachary A Yochum, Princey Devadassan, Eric H-B Huang, Ethan Miller, Roja Baruwal, Purva H Rumde, Autumn L GaitherDavis, Laura P Stabile, Timothy F Burns
TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer. Oncogene 43 (19) (2024)
Purva H Rumde, Timothy F Burns
A Path to Persistence after EGFR Inhibition. Cancer research 84 (8) (2024)
Vinod Kumar, Zachary A Yochum, Princey Devadassan, Eric H-B Huang, Ethan Miller, Roja Baruwal, Purva H Rumde, Autumn L GaitherDavis, Laura P Stabile, Timothy F Burns
TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer. Oncogene 43 (19) (2024)
Jaime L Schneider, Khvaramze Shaverdashvili, Mari A Mino-Kenudson, Subba R Digumarthy, Andrew Do, Audrey Liu, Justin F Gainor, Jochen K Lennerz, Timothy F Burns, Jessica J Lin
Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution. NPJ precision oncology 7 (1) (2023)
Shirish M Gadgeel, Jieling Miao, Jonathan W Riess, James Moon, Philip C Mack, Gregory J Gerstner, Timothy F Burns, Asma Taj, Wallace L Akerley, Konstantin H Dragnev, Noel Laudi, Mary W Redman, Jhanelle E Gray, David R Gandara, Karen Kelly
Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042). Clinical cancer research : an official journal of the American Association for Cancer Research (2023)